News

News
Share this article
26 July 2018

The European Lead Factory contributing to the fight against Alzheimer's

The key goal of ELF is to create validated hit series. Another successful ELF programme aimed at identifying small molecules for the treatment of Alzheimer’s Disease has culminated in the most potent compound yet identified by the ELF team at Newhouse, Scotland with the most active compound reaching 100pM. These compounds also have excellent physicochemical properties.

News
Share this article
10 July 2018

High number of SMEs benefit greatly from the European Lead Factory

The European Lead Factory is remarkably attractive for SMEs. The consortium consists of 30 partners, of which 10 are SMEs. They perform the screening and help to translate innovative design ideas into industry‐standard compound libraries. ELF is also interacting with a high number of SMEs who have enrolled via the target crowdsourcing route with in total 25 programmes (out of 88 programmes in the portfolio).

News
Share this article
07 June 2018

European Lead Factory reaches milestone of 200,000 novel compounds

Within a period of five years, the European Lead Factory (ELF) has reached one of its goals by completing the Public Compound Collection (PCC), comprising a commendable total of 200,000 novel compounds. The library production partners collaborated closely with the academic groups within ELF to reach this goal. The pan-European Public Chemistry Consortium is duly celebrating the achievement of this challenging objective.

News
Share this article
08 May 2018

Successful Stakeholder Meeting boosts energy for future collaborative drug discovery

On 16 and 17 April 2018 the European Lead Factory (ELF) Target Owner Workshop and Stakeholder Meeting took place in the heart of Europe, Brussels. An exciting row of speakers allowed for a retrospect on five years of successfully seeding and nursing innovative drug discovery projects. It also gave a hint about the future and how we can further grow the successful ELF platform to serve drug discovery for priority medicines.

News
Share this article
24 April 2018

Prof Adam Nelson wins UCB-Ehrlich Award for Excellence in Medicinal Chemistry

On April 19, Prof Adam Nelson, University of Leeds, won the UCB-Ehrlich Award for Excellence in Medicinal Chemistry. This award was established to acknowledge and recognise outstanding research in the field of Medicinal Chemistry, and is the most prestigious prize an academic medicinal chemist can get.

News
Share this article
13 April 2018

The future of the European Lead Factory – preparing the next phase

As a public-private partnership, the European Lead Factory (ELF) has already been instrumental in boosting early drug discovery. Its continuing goal is to offer unrivalled opportunities for the discovery of new lead drug lead molecules – to public and private organisations – in order to address unmet medical needs.

Press Release
Share this article
03 April 2018

Servier and Scandicure enter into agreement to conduct research in the field of metabolic diseases

Paris and Gothenburg, 3 April 2018 – Servier, an independent international pharmaceutical company, and Scandicure, a Swedish spin-out of the University of Gothenburg, today announced the establishment of an agreement to exploit Scandicure’s innovation in the field of metabolic disease.

News
Share this article
29 March 2018

Memorandum of Understanding between REDEFAR and ELF strengthens European connections

Prof Mabel Loza, coordinator of REDEFAR, the Spanish Network of Excellence in Drug Discovery, and the European Lead Factory executives Dr Dimitrios Tzalis and Dr Ton Rijnders have signed a Memorandum of Understanding for collaboration in future initiatives.

News
Share this article
29 March 2018

Chemistry partner EDELRIS praises collaboration within ELF

EDELRIS, a medicinal chemistry company, shares several LinkedIn posts explaining the key factors in the European Lead Factory that make their work possible. In their second post, EDELRIS tells more about their collaboration with the academic groups: 

News
Share this article
20 March 2018

Extraordinary hit compounds with API-like properties

At the end of 2017, Prof Reuven Stein received an extraordinary Qualified Hit List from the European Lead Factory. His research group studies the tumour microenvironment (TME) and has discovered a protein that plays an essential role in tumour progression. With the promising ELF compounds, they hope to develop new treatments for cancers such as glioma and melanoma.

Pages